If it wasn’t enough for Cargo Therapeutics to raise $200 million and recruit a C-suite of biopharma veterans so far this year, the CAR-T-focused company is now eying up an IPO.

Despite launching in 2021, the San Mateo, California-based biotech only came into view this past March, with a $200 million series A round co-led by Third Rock Ventures. Cargo has used the money to push its autologous CD22 CAR-T therapy into a phase 2 large B-cell lymphoma trial in August.

Now, it’s set its sights on the Nasdaq. While the company has yet to specify how much money it expects to raise from the offering, a prospectus filed with the SEC shows that Cargo intends to use proceeds from the IPO to continue the phase 2 trial, along with the funding goals of fueling internal R&D and potential licensing assets.

Its lead CAR-T, dubbed CRG-022, was licensed from the National Cancer Institute and Cargo hopes the therapy can address the “significant unmet need” of patients whose LBCL has relapsed or progressed despite receiving a CD19 CAR-T. An interim readout from the phase 2 study is expected in 2025.

Beyond relapsed/refractory LBCL, Cargo is also evaluating CRG-022’s potential in CAR-T naïve LBCL patients, as well as in B-cell acute lymphoblastic leukemia. Further behind in development is CRG-023, a trispecific CAR targeting CD19, CD20 and CD22 for which the company is preparing for IND-enabling studies.

Cargo is headed up by CEO Gina Chapman, who spent 15 years at Genentech. This year Chapman has recruited Chief Scientific Michael Ports, Ph.D., across from Janssen, where he served as head of cell therapy discovery and platforms, followed by Genentech alumni Ginna Laport, M.D., who was appointed chief medical officer last week.

While the icy IPO waters have thawed very slightly this year, it’s still relatively rare to see a biotech go public—especially while they are still riding high off a series A. There have been some positive stories, however, with radiopharmaceuticals-focused RayzeBio overshooting expectations last month to bring in $311 million from an IPO at a price of $18 per share.

But the risks remain, as demonstrated by Paris-listed biotech Abivax. The immunology-focused company’s share price plummeted almost 30% on Friday in the wake of its Nasdaq debut.

About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Related Services

Plasmids GMP Services

Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.

AAV GMP Services

Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
aav icon

Technology Platforms

PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.